Harrington Discovery Institute at University Hospitals and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2021 ADDF-Harrington Scholar Award .
| CLEVELAND, March 3, 2021 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2021 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer’s disease or related dementias. The Request for Proposal (RFP) is open to academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada, and the United Kingdom. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer’s field are encouraged to apply. The 2021 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia and is particularly seeking projects related to:
Other novel targets are encouraged. These include, but are not limited to, the following:
Award recipients will receive financial support up to $600,000 over two years, as well as drug development and project management support from Harrington Discovery Institute’s Therapeutics Development team. Proposals should offer creative science or novel approaches to treat, prevent, or slow Alzheimer’s disease or related dementias. Letters of Intent (LOI) will be accepted through April 23, 2021 5:00 pm EDT, and will be reviewed on a rolling basis prior to the deadline. LOI applications must be submitted online here. We encourage an interactive application process in efforts to solicit the best applications. Inquiries can be directed to either Andrew A. Pieper, MD PhD or Meriel Owen, PhD
SOURCE Harrington Discovery Institute |
View original content:
